Migraine Prevention: CGRP Inhibitors, Comparative Efficacy, and Treatment Selection
CGRP Pathway Targeting: Mechanism and Rationale
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide released from trigeminal sensory neurons during migraine attacks, promoting vasodilation and neurogenic inflammation. CGRP levels are elevated ictally and interictally in chronic migraine patients. Two therapeutic approaches target this pathway: monoclonal antibodies (mAbs) against CGRP itself (galcanezumab, fremanezumab, eptinezumab) or its receptor (erenumab), and small-molecule CGRP receptor antagonists (gepants) used for prevention (atogepant, rimegepant).
Monoclonal Antibody Efficacy: Head-to-Head Data
In the absence of large direct comparison trials, network meta-analyses provide the best available efficacy comparisons. All four mAbs reduce monthly migraine days (MMDs) by approximately 3.5-5.0 days in episodic migraine and 4.5-6.5 days in chronic migraine, with response rates (50% reduction in MMDs) of 45-62% versus 23-38% for placebo. Erenumab 140 mg showed a 50% responder rate of 50% in the STRIVE trial (episodic) and 41% in the CM trial (chronic). Galcanezumab 240/120 mg achieved 62% responder rates in EVOLVE-1 (episodic). Eptinezumab, the only IV formulation (100 or 300 mg quarterly), demonstrated efficacy as early as day 1 post-infusion in the PROMISE-1 and PROMISE-2 trials.
Gepant Preventives: Atogepant and Rimegepant
Atogepant (Qulipta, 10-60 mg daily) is the first oral CGRP receptor antagonist approved specifically for migraine prevention. The ADVANCE trial showed atogepant 60 mg reduced MMDs by 4.2 days versus 2.5 for placebo in episodic migraine (p<0.001). The PROGRESS trial extended this to chronic migraine, with a 7.5-day reduction in MMDs for the 60 mg dose. Rimegepant (Nurtec ODT, 75 mg every other day) holds dual approval for both acute treatment and prevention, reducing MMDs by 4.3 days versus 3.5 for placebo in the prevention trial (p=0.0099).
Sponsored
Treatment Selection: Practical Framework
For patients who prefer oral medication and value dual acute/preventive utility, rimegepant offers a unique profile. For patients who prefer monthly self-injection, erenumab, galcanezumab, or fremanezumab are reasonable first choices. Fremanezumab uniquely offers a quarterly dosing option (675 mg SC every 3 months). For patients with severe chronic migraine desiring rapid onset, eptinezumab IV provides the fastest documented effect. Prior failure of 2-3 oral preventives (topiramate, beta-blockers, amitriptyline) is typically required by US insurers before CGRP therapy authorization.
Safety Profile and Monitoring
Anti-CGRP mAbs have demonstrated a remarkably clean safety profile across open-label extension studies of up to 5 years. The most common adverse effects are injection-site reactions (erenumab, galcanezumab, fremanezumab) and constipation (erenumab, 3-4% vs 1% placebo). Hepatotoxicity is a theoretical concern with gepants based on early-generation oral CGRP antagonist data (telcagepant), but atogepant and rimegepant have not shown clinically significant hepatic signals. ALT monitoring is not required but reasonable in patients with baseline hepatic disease. No cardiovascular safety concerns have emerged, though theoretical CGRP blockade effects on wound healing and Raynaud phenomenon warrant ongoing surveillance.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.